Dual Sourcing: Strengthening the Pharmaceutical Supply Chain for Single-Use Assemblies

1640281789974

David Seifert

October 28, 2024

Table of contents

Show

Single Sourcing vs. Dual Sourcing

Do you remember when lead times were months instead of weeks? During the COVID-19 pandemic, biomanufacturers faced several significant supply chain challenges:

  • Lockdowns and restrictions led to disruptions in transportation and logistics, complicating the movement of raw materials and finished products. 
  • Increased demand for certain biomanufactured products such as vaccines or therapeutics often resulted in shortages of critical raw materials with long lead times.

For instance, bioprocess containers experienced lead times ranging from one to four months. Essential items like filter capsules, isolator technology, and assemblies sometimes had lead times extending from 14 up to 60 weeks. Additionally, there was a significant shortage of supplier specialists and engineers, which further complicated the process of setting up and stabilizing biomanufacturing processes. Increased shipping times and costs due to port congestion and limited freight capacity exacerbated these supply chain issues.

These challenges prompted many biomanufacturers to rethink their supply chain strategies, resulting in an emphasis on local sourcing, flexibility, and resilience to better prepare for future disruptions. This scenario brings us to dual sourcing and its capability to strengthen the robustness of the pharmaceutical supply chain.

Benefits of Dual Sourcing and Multi Sourcing

What do dual and multi-sourcing entail? These strategies are one of the core methods to strengthen the pharmaceutical supply chain.

  • Dual sourcing strategies involve obtaining a particular product or single-use system from two suppliers, ensuring continuity of supply for critical components.
  • Multi sourcing, on the other hand, involves sourcing from multiple suppliers, providing diverse quality levels, prices, or innovative features. Both strategies are vital for enhancing resilience and adaptability in global markets characterized by rapid changes and uncertainties.

Vendor independence is a crucial factor for enhancing supply chain robustness. It allows companies to negotiate better prices and terms, switch suppliers if costs rise, and maintain competitive expenses. In a dynamic environment where demand can fluctuate rapidly, having multiple vendors enables biomanufacturers to flexibly scale operations, avoiding bottlenecks and delays. Maintaining relationships with various vendors also provides more data and insights about the supply chain, improving decision-making, forecasting, and planning. Collaboration with different vendors can lead to better products and more efficient manufacturing processes.

Single Use Support Dual Sourcing Single Use Assemblies

Challenges in Pharmaceutical Procurement Strategies

However, dual and multi-sourcing programs present several challenges. A procurement strategy is much more than simply selecting new suppliers, as it involves ensuring timely delivery of quality medicines, and managing relationships to control costs.

The cost of validating a second source can be high, requiring evaluation of each supplier's materials, processes, and facilities. Transferring processes between suppliers can be complex due to unique technologies and equipment. Managing relationships with multiple suppliers increases communication complexity and administrative overhead. Despite these challenges, fostering competition between suppliers can lead to better pricing and terms.

Most dual and multi-sourcing programs are carried out through requests for quotations (RFQs) for single-use assemblies. Potential suppliers are identified based on their capabilities, compliance with regulatory requirements, and previous performance. The goal is to select suppliers that can meet quality standards, desired delivery times, and overall price expectations. The biopharmaceutical industry is highly regulated, necessitating strict adherence to quality and regulatory standards to ensure compliance.

Single Use Support Supply Chain in Pharmaceutical Industry

Supply Chain Resilience with Agnostic Integrator

An agnostic integrator plays a crucial role in this context. As a supplier-independent manufacturer, they provide customized single-use systems tailored to specific client needs, accommodating various biopharmaceutical processes. Their independence allows them to select the best components and materials from multiple sources, ensuring compatibility and functionality. They ensure their products meet stringent industry regulations and quality standards, handling testing and validation to provide assurance of correct and safe functioning in bioprocessing applications. Flexibility in testing and validation is a core competence of an integrator to meet quality requirements.

Agnostic Integrator between Manufacturer and Suppliers

Single Use Support as Robust Integrator

In conclusion, understanding the requirements for dual and multi-sourcing is essential for producing sterile consumables and single-use assemblies according to industry standards for filling systems, as well as upstream, downstream, and fill-finish processes.

One of Single Use Support’s core competencies is creating robust solutions using different market components swiftly. Our experience with multi-sourcing programs has provided insights into keeping these programs efficient and cost-effective. Partnering closely with customers and suppliers requires considerable effort but leads to more resilient and adaptable supply chains.

1640281789974

David Seifert

Head of Sales Application Engineering – Sterile Consumables

David Seifert is Head of Sales Application Engineering - Sterile Consumables. at Single Use Support. With proven expertise in the pharmaceutical, biotechnology industries, he advises pharma companies on fluid management equipment in manufacturing processes. As a single-use systems specialist, he has built extensive knowledge about aspetic and sterile drug manufacturing using single-use bioprocess containers and assemblies.

David is passionate about innovation, digitalization and solving customer challenges.

More from David Seifert

mRNA & LNPs.

RNase Contamination – Challenges & Solutions

This article explores the challenges posed by RNase contamination and the solutions that can be employed to mitigate these risks. RNase contamination | Ribonuclease inhibitors | RNase-free equipment

1640281789974

David Seifert

August 13, 2024

mRNA & LNPs.

RNase: Ribonuclease Simply Explained

RNase contamination can lead to the degradation of RNA, thereby compromising the efficacy of RNA-based drugs. Types of RNase | RNase and DNase | Role of DEPC

1640281789974

David Seifert

August 12, 2024

Read more about Fill & Filtration

Fill & Filtration

Aseptic filling machines for pharmaceutical liquids

Aseptic filling machines are widely adopted in the biopharma industry. From individual components and equipment to considerations like scalability – in this article, we will take a closer look at these systems.

micheal-eder

Michael Eder

January 16, 2024

Fill & Filtration

Aseptic filling & processing of biologics

Many drug products require aseptic conditions along their entire production process. In this article, we will discuss essential considerations on aseptic filling in the biopharma industry.

micheal-eder

Michael Eder

January 16, 2024

Fill & Filtration

Aseptic filling of large volumes of drug substances

Especially in large volume drug manufacturing, aseptic filling can be a challenging yet all the more important task to ensure product safety and effectiveness. In this article, we will discuss what manufacturers ought to be aware of.

micheal-eder

Michael Eder

January 16, 2024

Fill & Filtration

Automated aliquoting system - for small & large volumes

Be it small volume or bulk filling – aliquoting is a necessary step in biopharma manufacturing at every scale. In this article, we will cover the topic of automated aliquoting systems like RoSS.FILL.

micheal-eder

Michael Eder

November 14, 2023